KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata.

Rie Ueki, Masato Mizuashi, Kazutoshi Harada, Xingqi Zhang, Wenyu Wu, Wen-Hung Chung, Ohsang Kwon, Xin Luo, Victoria Basey, Robert Wolk, Nanzhi Shi, Kayo Fujita, Yimeng Shen, Tomohiro Hirose

J Dermatol 53(4) 578-586

PMID41645877
PMCIDPMC13075526
DOI10.1111/1346-8138.70154
发表日期2026-02-06
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:图注未提示 KM 曲线;FIGURE 3:图注未提示 KM 曲线;FIGURE 4:图注未提示 KM 曲线;FIGURE 5:图注未提示 KM 曲线。
摘要

摘要

Ritlecitinib is an oral JAK3/TEC family kinase inhibitor approved for individuals aged ≥ 12 years with severe alopecia areata. Here we report interim efficacy and safety results with ritlecitinib up to Month 24 in the Asian subpopulation from the ALLEGRO phase 2b/3 and ALLEGRO-LT studies. Data are reported for participants with Severity of Alopecia Tool score ≥ 50 who received ritlecitinib 50 mg with (200/50-mg group) or without (50-mg group) an initial 4-week 200-mg daily loading dose in ALLEGRO-2b/3, and continued ritlecitinib 50 mg in ALLEGRO-LT. In long-term studies, it is common for summaries at later time points to reflect participants who remained in the study, tolerated the drug, and had a positive treatment response. To account for this, efficacy summaries were presented both as observed and by using the last observation carried forward method. At Month 12, 51.7% and 44.7% (last observation carried forward) of Asian participants in the 50-mg (n = 58) and 200/50-mg groups (n = 47), respectively, achieved Severity of Alopecia Tool score ≤ 20 (≤ 20% scalp hair loss); the respective proportions were 50.0% and 47.8% at Month 24. Of participants who achieved Severity of Alopecia Tool score ≤ 20 at Month 12 in the 50-mg and 200/50-mg groups, 68.2% and 86.7% sustained this response through Month 24, respectively. At Month 12, 74.0% and 57.9% of participants in the 50-mg and 200/50-mg groups, respectively, had an eyebrow hair regrowth response; at Month 24, the proportions were 72.0% and 48.7%. At Month 12, 65.1% and 54.1% of participants in the 50-mg and 200/50-mg groups, respectively, had an eyelash hair regrowth response; the proportions were 65.1% and 52.8% at Month 24. The proportion of participants with a Patients' Global Impression of Change response of "moderately" or "greatly" improved since baseline increased through Month 24 in both groups. Ritlecitinib had an acceptable safety profile, consistent with that in the overall population. Overall, ritlecitinib 50 mg (±200-mg loading dose) demonstrated clinically meaningful and sustained efficacy through Month 24 in the Asian subpopulation, consistent with results in the overall population. Trial Registration: ClinicalTrials.gov: NCT04006457.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Participants from ALLEGRO‐2b/3 and ALLEGRO‐LT included in the Asian subpopulation analysis. *Data from participants in groups B, D, and E were not included in this analysis. **Data from participants in groups F and G while on placebo were not included in this analysis; data from participants in groups F and G were re‐baselined from the start of treatment with ritlecitinib.
非 KM Figure
FIGURE 2Proportion of participants with (A) a SALT score of ≤ 20 and (B) a SALT score of ≤ 10 through Month 24 in the Asian subpopulation. AA, alopecia areata; LOCF, last observation carried forward; SALT, Severity of Alopecia Tool. *Ritlecitinib 50 mg daily is the approved dose in Japan. † Number of participants with valid data at that analysis visit. ‡ Data while participants were on placebo were not included in this analysis; data from participants in groups F and G were re‐baselined from the start of treatment with ritlecitinib.
非 KM Figure
FIGURE 3Proportion of participants with (A) sustained SALT ≤ 20 response at Month 24 among those with SALT ≤ 20 response at Month 12* in the Asian subpopulation and (B) maintained SALT ≤ 20 response at Month 24 among those with SALT < 20 response at Month 12 in the Asian subpopulation † . SALT, Severity of Alopecia Tool. Percentages are based on n/N1 where n = the number of participants with sustained response and N1 = total number of participants with the observed value at Month 24. Observed data are presented. *Sustained SALT ≤ 20 response was defined as having a SALT score of ≤ 20 at Months 12 and 24 and not having a SALT score of > 20 at any time point between Months 12 and 24. † Maintained SALT ≤ 20 response was defined as having a SALT score of ≤ 20 at Months 12 and 24, regardless of whether the patient had a SALT score of > 20 at any time point between them.
非 KM Figure
FIGURE 4Proportions of participants with (A) eyebrow response (≥ 2‐grade improvement or normal EBA score) and (B) eyelash response (≥ 2‐grade improvement or normal ELA score) from baseline to Month 24 in the Asian subpopulation. (A) Eyebrow response. (B) Eyelash response. EBA, eyebrow assessment; ELA, eyelash assessment; LOCF, last observation carried forward. *Data while the participants were on placebo were not included in this analysis; data from participants in groups F and G were re‐baselined from the start of treatment with ritlecitinib. † Number of participants with valid data at that analysis visit.
非 KM Figure
FIGURE 5Proportions of participants with PGI‐C response* from baseline to Month 24 in the Asian subpopulation in ALLEGRO‐2b/3 and ALLEGRO‐LT clinical studies for AA. AA, alopecia areata; LOCF, last observation carried forward; PGI‐C, Patients' Global Impression of Change. PGI‐C response = score of “moderately” or “greatly” improved from baseline. The PGI‐C asks the participant to evaluate the improvement or worsening of AA symptoms compared with status at the start of the study. *Data while the participants were on placebo were not included in this analysis; data from participants in groups F and G were re‐baselined from the start of treatment with ritlecitinib. † Number of participants with valid data at that analysis visit.
非 KM Figure